- Email: [email protected]
Dyadic International reports 2014 year-end financial results
FOCUS Polypropylene catalysts market worth $1.123 bn by 2019 The report 'Polypropylene Catalysts Market by Type (Ziegler-Natta, Metallocene, and Co-Catalyst systems), by PP Manufacturing Process (Solvent, Bulk Slurry, and Gas phase) - Global trends & forecasts to 2019', published by MarketsandMarkets, reveals that the global polypropylene catalysts market is estimated at $840 M in 2014 and projected to reach a market size of $1.123 bn in 2019 registering a CAGR of 5%-6% between the same periods. Original Source: Marketsand Markets, 2015. Found on PR Newswire, 25 Mar 2015 (Website: http://www.prnewswire.com)
Strategic alliance to commercialize CFP process A development and commercialization agreement among Anellotech Inc, IFP Energies nouvelles, and its subsidiary Axens has been finalized. Under the deal, the catalytic fast pyrolysis (CFP) of non-food biomass of Anellotech will be used to develop a new technology to manufacture bio-based toluene, paraxylene, and benzene. Compared to petroleum-based counterparts, the new technology will be cost efficient in producing these bio-based products. Original Source: Biomass Magazine, Mar 2015, 9 (3), 9 (Website: http://biomassmagazine. com) © BBI International 2015
COMPANY NEWS Evonik wants to acquire Monarch Catalyst in India Evonik Industries AG, Essen (Germany), intends to strengthen its global catalysts business. On 11 Mar 2015, Evonik signed an agreement with Monarch Catalyst Pvt Ltd, Dombivli (India), to acquire 100% of the company's shares. The transaction is expected to close during 1H 2015 after the required approvals have been received. The parties have agreed to keep the purchase price confidential. Monarch's global oils and fats hydrogenation catalysts business, which has annual sales in the low
4
ON
C ATA LY S T S
double-digit million euro range, is a broadening of the Evonik catalysts portfolio and complements Evonik's leading positions in activated base metal catalysts and precious metal catalysts. Original Source: Evonik Industries, 11 Mar 2015 (Website: http://corporate.evonik.com/ en/) © Evonik Industries AG 2015. Original Source: Nachrichten fuer Aussenhandel, 11 Mar 2015 (Website: http://www. maerkte-weltweit.de) (in German) © MBM Martin Brueckner Medien GmbH 2015. Original Source: Evonik, 2015. Found on Special Chem Coatings and Inks Formulation, 13 Mar 2015 (Website: http://www. specialchem4coatings.com)
Dyadic International reports 2014 year-end financial results Dyadic International Inc, a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture, and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical, and industrial enzyme industries, announced financial results for the year ended 31 Dec 2014 (FY 2014). Total revenue for FY 2014 decreased to $12.5 M compared to $17.1 M for FY 2013. The decrease in total revenue is primarily due to the $6.0 M BASF upfront license fee in 2013. This decrease was partially offset by 53% growth in the company's research and development revenue of $710,000, and the receipt of $700,000 in milestone payments from Abengoa and BASF. Excluding the 2013 upfront BASF license fee, revenue increased $1.4 M, or 12% to $12.5 M compared to $11.1 M for the same period last year. Net product related revenue remained flat at $9.8 M. Sales for the period were driven by growth in the starch and alcohol markets, offset by lower sales to the textile market. License fee revenue for the nine months decreases $5.3 M due to the $6.0 M BASF upfront licensing fee in 2013. The $700,000 received in 2014 represents contractual payments of $500,000 from Abengoa for the first payment related to their Hugoton, KS facility, and a $200,000 payment from BASF for achieving its first research project milestone. Research and development revenue for 2014 increased $2.0 M compared to $1.3 M for 2013. The increase was primarily due to a higher number of externally
funded projects performed at its expanded research facility in the Netherlands. Gross profit for FY 2014 decreased to $4.3 M compared to $7.4 M for FY 2013. The decrease is due to the reduction of the 100% margin BASF upfront license fee of $6.0 M in 2013. Partially offsetting the effect of the decrease in license fee revenues, were higher gross profits from the product related sales, research and development revenues, and the first payments for the new Abengoa Hugoton facility and a research milestone from BASF. Excluding the 2013 upfront BASF licence fee, gross profit increases $2.9 M, or 208%, to $4.3 M compared to $1.4 M for the same period last year. Research and Development for FY 2014 was up 119% to $2.2 M. Overall operating expenses for FY 2014 increased 41% to $9.7 M compared to $6.9 M for the same period last year. Net loss for FY 2014 was $6.0 M, or ($0.18)/basic and diluted share, compared to a net loss of $428,000, or ($0.01)/basic and diluted share, for the same period a year ago. At 31 Dec 2014, cash and cash equivalents were $2.5 M compared to $8.9 M at 31 Dec 2013. During FY 2014, the company used approximately $6.4 M in cash and cash equivalents versus generating $4.9 M for FY 2013. Original Source: Dyadic International, 11 Mar 2015 (Website: http://dyadic.com/) © Dyadic International 2015. Original Source: Dyadic International Inc, 2015. Found on PR Newswire, 11 Mar 2015 (Website: http://www. prnewswire.com)
Partners sign new agreement for joint catalysis laboratory ’CaRLa’ in Heidelberg BASF and Heidelberg University have signed a new agreement for their joint catalysis laboratory 'Catalysis Research Laboratory' (CaRLa). The research cooperation at Heidelberg site ongoing since 2006 has been extended to Oct 2017. The CaRLa focuses on current topics in the field of homogeneous catalysis. CaRLa stands for the successful cooperation between academic and industrial research. At present, a jointly financed international team of eight doctorate level scientists, one engineer and the laboratory manager are working on developing new homogeneous May 2015
Strategic alliance to commercialize CFP process A development and commercialization agreement among Anellotech Inc, IFP Energies nouvelles, and its subsidiary Axens has been finalized. Under the deal, the catalytic fast pyrolysis (CFP) of non-food biomass of Anellotech will be used to develop a new technology to manufacture bio-based toluene, paraxylene, and benzene. Compared to petroleum-based counterparts, the new technology will be cost efficient in producing these bio-based products. Original Source: Biomass Magazine, Mar 2015, 9 (3), 9 (Website: http://biomassmagazine. com) © BBI International 2015
COMPANY NEWS Evonik wants to acquire Monarch Catalyst in India Evonik Industries AG, Essen (Germany), intends to strengthen its global catalysts business. On 11 Mar 2015, Evonik signed an agreement with Monarch Catalyst Pvt Ltd, Dombivli (India), to acquire 100% of the company's shares. The transaction is expected to close during 1H 2015 after the required approvals have been received. The parties have agreed to keep the purchase price confidential. Monarch's global oils and fats hydrogenation catalysts business, which has annual sales in the low
4
ON
C ATA LY S T S
double-digit million euro range, is a broadening of the Evonik catalysts portfolio and complements Evonik's leading positions in activated base metal catalysts and precious metal catalysts. Original Source: Evonik Industries, 11 Mar 2015 (Website: http://corporate.evonik.com/ en/) © Evonik Industries AG 2015. Original Source: Nachrichten fuer Aussenhandel, 11 Mar 2015 (Website: http://www. maerkte-weltweit.de) (in German) © MBM Martin Brueckner Medien GmbH 2015. Original Source: Evonik, 2015. Found on Special Chem Coatings and Inks Formulation, 13 Mar 2015 (Website: http://www. specialchem4coatings.com)
Dyadic International reports 2014 year-end financial results Dyadic International Inc, a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture, and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical, and industrial enzyme industries, announced financial results for the year ended 31 Dec 2014 (FY 2014). Total revenue for FY 2014 decreased to $12.5 M compared to $17.1 M for FY 2013. The decrease in total revenue is primarily due to the $6.0 M BASF upfront license fee in 2013. This decrease was partially offset by 53% growth in the company's research and development revenue of $710,000, and the receipt of $700,000 in milestone payments from Abengoa and BASF. Excluding the 2013 upfront BASF license fee, revenue increased $1.4 M, or 12% to $12.5 M compared to $11.1 M for the same period last year. Net product related revenue remained flat at $9.8 M. Sales for the period were driven by growth in the starch and alcohol markets, offset by lower sales to the textile market. License fee revenue for the nine months decreases $5.3 M due to the $6.0 M BASF upfront licensing fee in 2013. The $700,000 received in 2014 represents contractual payments of $500,000 from Abengoa for the first payment related to their Hugoton, KS facility, and a $200,000 payment from BASF for achieving its first research project milestone. Research and development revenue for 2014 increased $2.0 M compared to $1.3 M for 2013. The increase was primarily due to a higher number of externally
funded projects performed at its expanded research facility in the Netherlands. Gross profit for FY 2014 decreased to $4.3 M compared to $7.4 M for FY 2013. The decrease is due to the reduction of the 100% margin BASF upfront license fee of $6.0 M in 2013. Partially offsetting the effect of the decrease in license fee revenues, were higher gross profits from the product related sales, research and development revenues, and the first payments for the new Abengoa Hugoton facility and a research milestone from BASF. Excluding the 2013 upfront BASF licence fee, gross profit increases $2.9 M, or 208%, to $4.3 M compared to $1.4 M for the same period last year. Research and Development for FY 2014 was up 119% to $2.2 M. Overall operating expenses for FY 2014 increased 41% to $9.7 M compared to $6.9 M for the same period last year. Net loss for FY 2014 was $6.0 M, or ($0.18)/basic and diluted share, compared to a net loss of $428,000, or ($0.01)/basic and diluted share, for the same period a year ago. At 31 Dec 2014, cash and cash equivalents were $2.5 M compared to $8.9 M at 31 Dec 2013. During FY 2014, the company used approximately $6.4 M in cash and cash equivalents versus generating $4.9 M for FY 2013. Original Source: Dyadic International, 11 Mar 2015 (Website: http://dyadic.com/) © Dyadic International 2015. Original Source: Dyadic International Inc, 2015. Found on PR Newswire, 11 Mar 2015 (Website: http://www. prnewswire.com)
Partners sign new agreement for joint catalysis laboratory ’CaRLa’ in Heidelberg BASF and Heidelberg University have signed a new agreement for their joint catalysis laboratory 'Catalysis Research Laboratory' (CaRLa). The research cooperation at Heidelberg site ongoing since 2006 has been extended to Oct 2017. The CaRLa focuses on current topics in the field of homogeneous catalysis. CaRLa stands for the successful cooperation between academic and industrial research. At present, a jointly financed international team of eight doctorate level scientists, one engineer and the laboratory manager are working on developing new homogeneous May 2015